The potential of Panax notoginseng against COVID-19 infection

Yeye Hu; Ziliang He; Wei Zhang; Zhiqiang Niu; Yanting Wang; Ji Zhang; Ting Shen; Hong Cheng; Weicheng Hu

doi:10.1016/j.jgr.2023.04.002

The potential of Panax notoginseng against COVID-19 infection

J Ginseng Res. 2023 Apr 8;47(5):622-626. doi: 10.1016/j.jgr.2023.04.002. Online ahead of print.

Authors

Yeye Hu¹, Ziliang He², Wei Zhang², Zhiqiang Niu¹, Yanting Wang¹, Ji Zhang², Ting Shen¹, Hong Cheng¹, Weicheng Hu^{1

3

4}

Affiliations

¹ Institute of Translational Medicine, School of Medicine, Yangzhou University, Yangzhou, 225009, China.
² School of Life Sciences, Huaiyin Normal University, Huaian, 223300, China.
³ Affiliated Hospital of Yangzhou University, Yangzhou, 225009, China.
⁴ Jiangsu Key Laboratory of Experimental & Translational Non-Coding RNA Research, School of Medicine, Yangzhou University, Yangzhou, 225009, China.

Abstract

The COVID-19 pandemic has changed the world and has presented the scientific community with unprecedented challenges. Infection is associated with overproduction of proinflammatory cytokines secondary to hyperactivation of the innate immune response, inducing a cytokine storm and triggering multiorgan failure and significant morbidity/mortality. No specific treatment is yet available. For thousands of years, Panax notoginseng has been used to treat various infectious diseases. Experimental evidence of P. notoginseng utility in terms of alleviating the cytokine storm, especially the cascade, and improving post-COVID-19 symptoms, suggests that P. notoginseng may serve as a valuable adjunct treatment for COVID-19 infection.

Keywords: COVID-19; Panax notoginseng; cytokine storm; potential therapeutics.

Publication types

Review